IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test. The results from this...
Results from a published multicenter study The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow. Urine samples were...
The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was...